Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 4 Thyroid Carcinoma, Anaplastic 3 Neoplasms 3 Glioma 3 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Recurrence 1 Rare Malignant Neoplasm 1 Oligodendroglioma 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neurocytoma 1 Neuroblastoma 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Locally Advanced Thyroid Gland Carcinoma 1 Histiocytosis, Langerhans-Cell 1 Hematologic Neoplasms 1 Glioblastoma 1 Ganglioneuroma 1 Ganglioglioma 1 Eunuchism 1

Interventions

Cyclophosphamide 21 venetoclax 18 pembrolizumab 16 Dexamethasone 16 fludarabine 14 Cytarabine 13 Gemcitabine 9 pomalidomide 8 Rituximab 8 Carboplatin 8 Azacitidine 8 glofitamab 7 fludarabine phosphate 7 Lenalidomide 7 Immunotherapy, Adoptive 7 selinexor 6 Paclitaxel 6 Injections 6 Granulocyte Colony-Stimulating Factor 6 Cisplatin 6 daratumumab 5 Temozolomide 5 Oxaliplatin 5 Bevacizumab 5 zanubrutinib 4 ruxolitinib 4 Surgical Procedures, Operative 4 Nivolumab 4 Drug Therapy 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × dabrafenib × Clear all

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡